Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 345Gastrointestinal 12Gynecologic 10Breast 7Head & Neck 6Genitourinary 6CNS 6Dermatologic 3Sarcoma 2NET 2Endocrine 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neuroendocrine Tumors 7Lung Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Large Cell 1

Interventions

Paclitaxel 2Carboplatin 2taxane 1romidepsin 1repotrectinib 1pralsetinib 1liposomal doxorubicin 1atezolizumab 1Vinorelbine 1Temozolomide 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Oxaliplatin 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lactones 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Etoposide 1Drug Therapy 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Carboplatin × NET × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡